Drugs / EFMITERMANT ALFA
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02257489 | Sep 2014 → Mar 2016 | musculoskeletal system disorder | Acceleron Pharma, Inc. | Completed | No outcome recorded |
| Phase 23 trials · 2 met primary | ||||||
| Phase 2 | NCT03943290 | May 2019 → Mar 2020 | Charcot-Marie-Tooth disease, facioscapulohumeral muscular dystrophy | Acceleron Pharma, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03124459 | Jul 2017 → Mar 2020 | Charcot-Marie-Tooth disease | Acceleron Pharma, Inc. | Terminated | Met primary |
| Phase 2 | NCT02927080 | Nov 2016 → Sep 2019 | facioscapulohumeral muscular dystrophy | Acceleron Pharma, Inc. | Terminated | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EFMITERMANT ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297867 ↗ |
| Known as | ACE-083 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03124459 ↗ |
| Modality | Protein / enzyme biologic | “recombinant fusion protein” NCT02257489 ↗ |
| Route | Intramuscular | “administered unilaterally or bilaterally to either the tibialis anterior (TA) or biceps brachii (BB) muscle(s)” NCT02927080 ↗ |